The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 3, 2002, Pages 1282-1290

  Egan, Josephine M ^a   Clocquet, Astrid R ^b   Elahi, Dariush ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0036965113     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.3.8337     Document Type: Article

References (11)

1. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W 1993 Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
2. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendiæ S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
3. Meneilly GS, McIntosh CHS, Pederson RA, et al. Effect of glucagon-like peptide-1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care, in press
4. Greig N, Holloway HW, De Ore KA, et al. 1999 Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50
5. Young AA, Gedulin BR, Bhavsar S, et al. 1999 Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034
6. Elahi D 1996 In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 19:278-286
7. Ryan AS, Egan JM, Habener JF, Elahi D 1998 Insulinotropic hormone glucagon like peptide-1 (7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 83:2399-2409
8. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. 1993 The effect of recombinant human IGF-1 on glucose and leucine kinetics in man. Am J Physiol 265:E831-E838
9. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. 1994 The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74
10. Nauck MA, Niedereichholz U, Ettler R, et al. 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
11. Thorens B, Porret A, Bühler L, et al. 1993 Cloning and functional expression of the human islet GLP-1 receptor. Diabetes 42:1678-1682